A new Risk Evaluation and Mitigation Strategy (REMS) will aim to reduce the misuse of long-acting opioids
A new Risk Evaluation and Mitigation Strategy (REMS) will aim to reduce the misuse of long-acting opioids.
Unintentional deaths due to opioids have quadrupled in 8 years...and treatment for opioid abuse has increased five-fold in 10 years.
Now FDA will require manufacturers to come up with a REMS plan by mid-August...with the changes rolled out by early 2012.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote